Drugs / bireociclib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04539496 | May 2018 → Jul 2023 overdue | breast cancer, metastatic neoplasm | Sihuan Pharmaceutical Holdings Group Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bireociclib | “Bireociclib (XZP-3287) is a novel selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies.” PMID 40013319 ↗ Feb 2025 |
| Known as | XZP-3287 | “Bireociclib (XZP-3287) is a novel selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies.” PMID 40013319 ↗ Feb 2025 |
| Action | Inhibit | “the novel selective small molecule CDK4/6 inhibitor bireociclib” PMID 41063198 ↗ Oct 2025 |
| Modality | Small molecule | “the novel selective small molecule CDK4/6 inhibitor bireociclib” PMID 41063198 ↗ Oct 2025 |
| Target | CDK4 | “the novel selective small molecule CDK4/6 inhibitor bireociclib” PMID 41063198 ↗ Oct 2025 |